Drug Approval | January 24, 2026
Sun Pharma gets DCGI nod to launch generic Semaglutide injection for weight loss in India
Company to launch product after the expiry of semaglutide patent in India
Company to launch product after the expiry of semaglutide patent in India
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
EMA recommended 30 veterinary medicines for marketing authorisation in 2025
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
Experts caution that realizing AI’s potential requires careful management and risk mitigation
WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation
Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,
The decision secures legal protection in China for semaglutide, the blockbuster drug underpinning Novo Nordisk’s diabetes and obesity treatments
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
Subscribe To Our Newsletter & Stay Updated
